<DOC>
	<DOCNO>NCT00536809</DOCNO>
	<brief_summary>The purpose study determine high , tolerate dose level safety lapatinib , capecitabine oxaliplatin subject advance cancer determine clinical activity combination drug subject previously untreated advanced metastatic colorectal cancer .</brief_summary>
	<brief_title>Phase I/II Study Lapatinib Combination With Oxaliplatin Capecitabine Subjects With Advanced Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Inclusion criterion 1 . 18 year age old . 2 . A female eligible enter participate study : Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) , include female : Has hysterectomy , Has bilateral oophorectomy ( ovariectomy ) , Has bilateral tubal ligation , Is consider postmenopausal ( define amenorrheic great equal 1 year ) . Childbearing potential , negative serum pregnancy test Screening agree one follow 2 week prior enrolment continue poststudy visit : Complete abstinence sexual intercourse Oral Contraceptive , either combined progestogen alone ( must use back method , take less 3 cycle ) Injectable progestogen Implants levonorgestrel Estrogenic vaginal ring Percutaneous contraceptive patch Intrauterine device ( IUD ) intrauterine system ( IUS ) document failure rate le 1 % per year Male partner sterilization ( vasectomy documentation azoospermia ) prior female subject 's entry study , male sole partner subject Double barrier method : condom occlusive cap ( diaphragm cervical/vault cap ) plus spermicidal agent ( foam/gel/film/cream/suppository ) 3 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status less equal 2 . 4 . Provided write informed consent . 5 . Hemoglobin great equal 8 gm/dL ( 5 nmol/L ) , clinically stable . 6 . Absolute neutrophil count great equal 1,500/mm^3 ( 1.5 x 109/L ) . 7 . Calculated creatinine clearance ( CrCl ) great equal 50 mls/min . 8 . Total bilirubin less equal 1.25 time institutional upper limit normal ( ULN ) . 9 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) less equal 2 time ULN . For subject liver metastasis : AST ALT less equal 5 time ULN . 10 . LVEF great equal 50 % great equal LLN institution base multiple gated acquisition scan ( MUGA ) echocardiogram ( ECHO ) . Specific Phase I : 11 . Recurrent , advance , metastatic cancer know potentially responsive treatment fluoropyrimidines oxaliplatin . Examples include gastrointestinal tumor , HER2 ( ErbB2 ) positive breast cancer , lung cancer . 12 . Received less equal 3 prior chemotherapy regimen without pelvic radiotherapy less equal 2 prior chemotherapy regimens receive pelvic radiotherapy . 13 . Platelet count great equal 75,000/mm^3 ( 75 x 109/L ) . Specific Phase II : 14 . Histologicallyconfirmed , measurable advanced metastatic CRC previously untreated metastatic set 6 month post oxaliplatincontaining adjuvant therapy . 15 . Archived paraffinembedded tumor tissue must available biomarker analysis . 16 . Platelet count great equal 100,000/mm^3 ( 100 x 109/L ) . Exclusion Critera : 1 . Pregnant lactate female . 2 . Prior resection small bowel . 3 . Brain metastasis require additional treatment . 4 . Medically unfit study result medical interview , physical exam , screen investigation . 5 . Taking medication prohibit medication list ( see Section 9.2 ) . 6 . History drug allergy , , opinion Investigator , contraindicate participation . 7 . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate study drug . These include anilinoquinazolines , gefitinib [ Iressa ] , erlotinib [ Tarceva ] . The subject receive treatment investigational drug previous four week . 8 . Treatment biologic , cytotoxic , radiation , hormonal ( contraception replacement ) therapy within four week . Treatment hormones short halflives allow 1 week prior study treatment consultation GSK medical monitor . 9 . Major surgery within previous two week unless opinion Investigator , subject recover sufficiently begin study treatment . 10 . Physiological , familial , sociological , geographical condition permit compliance protocol . 11 . Receiving concurrent coumadin therapy . Minidose coumadin maintenance catheter ( 0.5 1.0 mg/day ) , anticoagulation therapy allow study . Subjects receive minidose coumadin must prothrombin time ( PT ) International normalize ratio ( INR ) partial thromboplastin time ( PTT ) within 1.2 time ULN . 12 . History uncontrolled symptomatic angina , arrhythmia , congestive heart failure . 13 . Corrected QT interval ( QTc ) great 450 msec . Specific Phase I : 14 . Residual chemotherapy relate toxicity great equal Grade 2 clinically felt likely exacerbate treatment regimen . Specific Phase II ( amendment write completion Phase 1 ) : 15 . Have current active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , liver metastasis stable chronic liver disease per investigator assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>fluoropyrimidines cancer</keyword>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>Advanced Colorectal Cancer</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>lapatinib</keyword>
	<keyword>capecitabine</keyword>
</DOC>